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The question as to whether free radical reactions are a major cause of tissue injury in human disease, or 
merely an accompaniment to such injury, is very difficult to answer because of lack of adequate xperimental 
techniques. New techniques that are becoming available are discussed, with specific reference to their use 
in humans. 
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1. INTRODUCTION 
There is a massive literature concerning the role 
of free radical reactions in human disease; table 1 
lists some of the conditions in which free radical 
involvement has been proposed. A question arises 
as to whether radical production in many diseases 
is a major cause of tissue injury or merely a conse- 
quence of it [1,2,64,65]. Attempts to answer this 
question are currently hampered by lack of ade- 
quate methodology, although the reports of Ames 
et al. [31,32] that bacterial cells respond rapidly to 
oxidative stress by synthesis of specific ‘alarmone’ 
molecules may be of great importance in the 
future, provided that such molecules are also made 
in animal cells. 
A common current approach is to try to 
measure end-products of lipid peroxidation in 
human body fluids or tissue extracts. Unfortunate- 
ly, the commonly used ‘TBA test’ is unspecific and 
can give misleading results [3,12] and measurement 
of UV-absorbing ‘diene conjugates’ may in fact be 
measuring something in human fluids that does 
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not arise by lipid peroxidation [4]. Corongiu et al. 
[5] have introduced an interesting modification of 
the diene conjugate method, but its applicability to 
human body fluids is presently unclear [4]. 
Analysis of polyunsaturated fatty acid changes in 
membrane lipids often gives interesting results, but 
many diseases and toxins alter the activity of fatty 
acid synthetase/desaturase enzymes, changing the 
rate of membrane lipid turnover. Determination of 
specific peroxidation end-products, arising from 
such cytotoxic aldehydes as 4-hydroxynonenal, 
may prove in future to be an excellent assay 
method [7,8], as may enzymic determination of 
lipid peroxides [9]. Hydrocarbon gas exhalation 
[10,60] is a useful assay for animals, but very dif- 
ficult to apply to humans except under carefully 
controlled laboratory conditions, and so not 
suitable for routine studies. Light emission shows 
considerable promise as an assay of lipid peroxida- 
tion, and perhaps other free radical reactions, in 
cells and perfused organs [ 1 I], but again might 
prove difficult to apply to humans, although the 
pace of advance in fibre-optic technology is so 
great that one cannot rule it out. 
One problem in relying on measurements of 
lipid peroxidation as an index of free radical reac- 
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Table 1 
Some clinical conditions in which the involvement of oxygen radicals has been suggested 
Inflammatory-immune injury 
Glomerulonephritis (idiopathic, 
membranous) 
Vasculitis (hepatitis B virus, drugs) 
Autoimmune diseases 
Rheumatoid arthritis 
Ischemia - reflow states 
Stroke/myocardial infarction 
Organ transplantation 
Drug- and toxin-induced reactions 
Iron overload 
Idiopathic haemochromatosis 
Bantu tribe iron pot beer drinkers 
Thalassaemia and other chronic 
anaemias treated with multiple 
blood transfusions 
Nutritional deficiencies (Kwashiorkc 
Alcoholism 
Radiation injury 
Ageing 
Disorders of ‘premature ageing’ 
Red blood cells 
Phenylhydrazine 
Primaquine, related drugs 
Lead poisoning 
Protoporphyrin photo-oxidation 
Malaria 
Sickle cell anaemia 
Favism 
Fanconi’s anaemia 
Lung 
Cigarette-smoke ffect 
Emphysema 
Hyperoxia 
Bronchopulmonary dysplasia 
Oxidant pollutants (03) 
ARDS (some forms) 
Mineral dust pneumoconiosis 
Bleomycin toxicity 
SO2 toxicity 
Heart and cardiovascular system 
Alcohol cardiomyopathy 
Keshan disease (selenium deficiency) 
Atherosclerosis 
Adriamycin cardiotoxicity 
Kidney 
Autoimmune nephrotic syndromes 
Aminoglycoside nephrotoxicity 
Heavy metal nephrotoxicity 
If) 
Gastrointestinal tract 
Endotoxin liver injury 
Halogenated hydrocarbon liver injury 
(e.g. bromobenzene, CCL, 
halothane) 
Diabetogenic action of alloxan 
FFA-induced pancreatitis 
NSAID-induced G + I tract lesions 
Oral iron poisoning 
Brain 
Hyperbaric oxygen 
Vitamin E deficiency 
Neurotoxins 
Parkinson’s disease 
Hypertensive cerebrovascular injury 
Neuronal ceroid lipofuscinoses 
Allergic encephalomyelitis and other 
demyelinating diseases 
Aluminium overload 
Potentiation of traumatic injury 
Eye 
Cataractogenesis 
Ocular haemorrhage 
Degenerative retinal damage 
Retinopathy of prematurity 
Photic retinopathy 
Skin 
Solar radiation 
Thermal injury 
Porphyria 
Hypericin, other photosensitizers 
Contact dermatitis 
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tions is that, in most (not all [22]) cases of ‘ox- 
idative stress’, lipid peroxidation is probably not 
the major mechanism by which increased genera- 
tion of oxygen-derived species causes primary 
cellular injury. For example, the toxicity of para- 
quat to lung involves 02 and H202, but the tissue 
damage may be mediated by depletion of 
nicotinamide nucleotides and/or inhibition of lipid 
synthesis rather than by lipid peroxidation ([13] lot 
cit.) Similarly, lipid peroxidation occurs at a late 
stage in paraquat-treated plants; the primary 
mechanism of damage seems to be direct inactiva- 
tion of Calvin cycle enzymes by increased Hz02 
formation [ 141. Inhibition of lipid peroxidation by 
antioxidants does not abolish the toxicity of MPP+ 
[ 151, mercury [16] or thiol-modifying reagents [17] 
to hepatocytes, nor can the toxicity of Hz02 [29], 
paracetamol [55], diquat [19], hyperoxia [19] or, 
possibly [61], bromobenzene [18] to these cells be 
attributed to lipid peroxidation. Excessive GSH 
depletion [19,29] and/or DNA damage [20], 
perhaps leading to lethal depletions of 
nicotinamide nucleotides as poly(ADP-ribose) syn- 
thetase is activated [21,30], and/or to impairments 
in the regulation of intracellular Ca2+ concentra- 
tion, may be the primary toxic mechanisms. 
Poisonous end-products of lipid peroxidation, 
such as unsaturated aldehydes, may be of some im- 
portance in spreading injury away from the cells 
first damaged [22,56,59], but measuring such end- 
products may be looking at something that is 
remote from what triggered the injury initially. 
Hence it can be argued that studying lipid perox- 
idation in whole subjects will not lead to a resolu- 
tion of the ‘cause or consequence’ question posed 
at the beginning of this article, since lipid perox- 
idation is usually a late event. In any case, the 
methods most frequently used currently are prob- 
ably inadequate (see above) to track accurately the 
rate of peroxidation in the whole body. 
2. WHAT CAUSES CELLULAR DAMAGE? 
The cellular injury produced by hyperoxia and 
redox-cycling drugs involves increased generation 
of superoxide radical (02) and Hz02 ([28] lot cit.). 
Both of these have some direct damaging effects 
[28] and Hz02 can deplete GSH as it is metabolized 
by glutathione peroxidase, but we believe that a 
key mechanism of toxicity is the metal-ion- 
dependent formation of highly reactive hydroxyl 
radical, ‘OH, or a species of similar reactivity 
[2,23]. In the absence of precise chemical informa- 
tion as to what such an alternative species might 
be, we shall continue to refer to ‘OH, although the 
argument would not be altered if “OH’ turned out 
to be a different reactive radical. Hence the loca- 
tion of metal-ion complexes capable of causing 
‘OH radical formation will influence the type of 
damage that is done by oxidative stress [23,24]; 
DNA seems often to have such metal complexes at- 
tached to it in vivo [20,63] and so oxidative stress 
may lead to DNA damage and consequent lethal 
nicotinamide nucleotide depletion (see above). 
Thus chelating agents, such as desferrioxamine 
[25], that are capable of preventing metal- 
dependent ’ OH radical generation can minimize 
damage by 02 and HzOz, both in cellular systems 
(e.g. [19,20,37]) and in whole animals (reviewed in 
[23,24]). It must be recognised that chelating 
agents such as desferrioxamine may have multiple 
mechanisms of action [23-261 and often cannot 
get to the correct sites [20]. Desferrioxamine itself 
is unlikely to be of use for human therapy [27] and 
more promising agents exist [58], but the signifi- 
cant protective effects of desferrioxamine observed 
in whole animal models of human disease are con- 
sistent with our view [2,23-251 that metal- 
dependent ‘OH formation is an important cytotox- 
ic mechanism and does contribute significantly to 
tissue damage in several human diseases. Superox- 
ide dismutase and HzOz-removing systems might 
also be of therapeutic importance, as may in- 
hibitors of radical-generating enzymes (reviewed in 
[57,581). 
3. CAN HYDROXYL RADICAL BE 
MEASURED IN VIVO? 
3.1. Principles 
Hydroxyl radical is so highly reactive that 
measuring its formation in vivo will be corre- 
spondingly difficult. Its formation cannot be infer- 
red from protective effects of “OH scavengers’ 
(such as dimethyi sulphoxide, thiourea or di- 
methylthiourea) in animal models of human 
disease, since these molecules react with many 
other species. For example, thiourea combines 
with Hz02 and scavenges hypochlorous acid 
produced by the myeloperoxidase system [33]. At 
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present, only mannitol and formate remain as 
specific scavengers of ‘OH, but formate is 
metabolised rapidly in vivo to CO2 by formate 
dehydrogenases and the peroxidatic action of 
catalase, whereas mannitol does not enter cells 
easily. Several in vitro assays for ‘OH, such as 
dimethyl sulphoxide oxidation [35,36], ethylene 
formation [34,36] or spin-trapping [38-401 do not 
seem applicable for use to detect *OH in humans, 
although they may be of value for isolated cells 
and, perhaps, for perfused organs, and spin-traps 
can detect carbon-centred radicals in whole 
animals ([62] lot cit.). 
extracts, and one or more of these products is not 
identical to enzyme-produced hydroxylated 
products, then formation of the ‘unnatural’ 
products could conceivably be used to assess ‘OH 
radical formation in vivo. This assumes that the 
aromatic detector molecule is present at the sites of 
‘OH radical generation at concentrations ufficient 
to compete with any other molecules that might 
scavenge ‘OH, and that any unnatural hydrox- 
ylated product is not immediately metabolised. 
The molecules used as ‘aromatic detectors’ might 
be ‘foreign’ substances administered to the sub- 
jects orally or by injection, or they might be 
substances present endogenously. 
3.2. DNA dumage 
If DNA is an important cellular target for attack 
by ‘OH or related radical species, can the products 
of attack be measured? This approach was 
pioneered by Ames et al. [41], who measured 
thymine and thymidine glycol, as products of ox- 
idative DNA damage, in human urine. The assay 
method in 1411 is very tedious however, although 
measurement of hydroxymethyluracil may be an 
improvement [42]. 8_Hydroxyguanosine, another 
product of ‘OH radical attack on DNA [43], might 
be measured [44]. Dizdaroglu 145,461 has described 
detailed methods for studies of the products of 
radical attack on DNA samples. Of course, use of 
such methods in humans requires access to DNA 
samples from the tissue suspected of being under 
radical attack unless one is lucky enough to find a 
product that is cleaved out of DNA and excreted 
unchanged. Leucocytes and placenta are easily 
available, and biopsies of liver, skin and muscle 
can often be obtained, but samples of other organs 
are difficult to obtain. 
3.3.1. Administered substances 
Under physiological conditions, attack of ‘OH 
upon salicylate produces three products (fig. 1). 
The major products are 2,3- and 2,5dihydroxy- 
benzoates, but a small amount of catechol is 
formed by de~arboxylation 1501. 2,3-Dihydroxy- 
benzoate has not been reported as an enzyme- 
produced metabolite of salicylate, although 2,5-di- 
hydroxybenzoate has. Since low concentrations of 
2,3-dihydroxybenzoate can be detected in human 
plasma [51] and urine 1521 of normal subjects and 
rheumatoid patients consuming aspirin (O-acetyl- 
salicylate), and there appears to be an increased 
formation of 2,3-dihydroxybenzoate in patients 
with active rheumatoid disease, in which free 
radical production by neutrophils is known to be 
3.3. Aromatic hydroxyiut~on 
Under physiological conditions, attack of ‘OH 
radical on molecules containing benzene rings 
results largely in formation of hydroxylated 
products [47]. Indeed, aromatic hydroxylation has 
been used as a method for measuring ‘OH radical 
production in vitro [48,49]. Suitable non-toxic 
aromatic compounds for use in measuring *OH 
production by whole cells and perfused organs in- 
clude salicylate [50] and phenylalanine [47]. 
2,3-Dthydroxybenzoate 
If an aromatic compound reacts with ‘OH to 2,5-D~hydroxybenzoate 
form a specific set of hydroxylated products that Fig.1. Products of the attack of hydroxyl radical on 
can be accurately measured in body fluids or tissue salicylate. 
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PHE 
Fig.2. Products of the attack of hydroxyl radical on 
0 6 OH o-TYR 
/ 
pheny~~anine. o-Tyr (orf~o-tyrosine); m-Tyr (mera- 
tyrosine); p-Tyr (para-tyrosine, the ‘real tyrosine’). 
greatly increased [2], it is possible that 2,3-dihy- 
droxybenzoate might be a product of ‘OH attack 
on the salicylate molecule. It might also be 
produced as a minor, previously unrecog~ised, 
product of saiicyiate metabolism, a possibility we 
must always bear in mind. Many non-steroidal 
anti-inflammatory drugs other than aspirin con- 
tain aromatic rings, and products of attack of ‘OH 
upon them are under investigation in our 
laboratory. 
Attack of ‘OH, generated by a Fenton system at 
pH 7.4, upon phenylalanine also produces three 
products (fig.2). Phenylalanine is less toxic to cer- 
tain cell types than is salicylate, does not interfere 
with arachidonic acid metabolism, and is very 
useful for measuring ‘OH production in vitro 1471. 
Whether it can be used in vivo is debatable; con- 
centrations of phenylalanine normally present in 
human body fluids and cells are probably too low 
to intercept ‘OH, and administration of large 
doses of phenylalanine to humans may be difficult 
to justify. 
3.3.2. Endogenous substances 
Determination of products of ‘OH radical at- 
tack upon DNA (see above) could be classified 
under this heading. Another substance present in 
human body fluids, and thought to function as an 
antioxidant in vivo, is uric acid [53]. A major 
product of radical attack upon uric acid is allan- 
toin [53,54]. Methods have been developed for the 
measurement of allantoin in human body fluids, 
and the results suggest an increased conversion of 
uric acid into allantoin during active rheumatoid 
disease [54]. We have recently found that different 
radical species give different ratios of allantoin to 
other oxidation products from uric acid. Deter- 
mination of these other oxidation products might, 
we hope, give information about the specific 
radical species that cause uric acid oxidation in 
vivo . 
4. CONCLUSION 
Many laboratories [3-11,31,32,36,41-47,51, 
52,541 have recognised that further developments 
in our understanding of the role of free radicals in 
human disease require better experimental tools. A 
major effort is required to evaluate the many pro- 
mising new techniques discussed above. The 
striking effects observed with SOD in protection 
against reoxygenation injury [57], and with metal- 
chelating agents 1271, shows the great therapeutic 
potential of interfering with free radical reactions. 
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